Clinical trial
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone…
NCT00031915 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00031915 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma |
| Official title | Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Start date | Jun 1, 2002 |
| Completion | May 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: